K

Keck School of Medicine of USC | Neurology Department

Research site
(Unclaimed)
Location
1520 San Pablo Street, Suite 3000, Los Angeles, California, United States of America
Site insights

Top conditions

Hearing Loss (3 trials)

Fibrosis (3 trials)

Eczema (2 trials)

Parkinson Disease (2 trials)

Lung Cancer (2 trials)

Top treatments

Encorafenib
Macitentan
PF-07242813
Resmetirom
Eptinezumab
Bromocriptine
AlloGen
Ustekinumab
GLPG1690
BCA101

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

13 of 35
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the t...

Enrolling
Metastatic Colorectal Cancer
Biological: Pembrolizumab
Biological: Cetuximab

The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround fl...

Enrolling
Drug Refractory Paroxysmal Atrial Fibrillation
Device: TRUPULSE Generator
Device: THERMOCOOL STSF Bi- Directional Navigation Catheter

This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomipzomib or placebo in additi...

Enrolling
Autoimmune Hepatitis
Drug: zetomipzomib
Drug: zetomipzomib in open-label extension

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with gene...

Enrolling
Generalized Myasthenia Gravis
Drug: Satralizumab
Other: Placebo

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab...

Active, not recruiting
Parkinsons Disease
Drug: Prasinezumab
Drug: Placebo

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib
Locations recently updated

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth...

Active, not recruiting
Breast Neoplasm
Neoplasm Metastasis
Drug: Placebo
Drug: Abemaciclib

This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.

Enrolling
Kidney Transplant Rejection
Drug: Tacrolimus
Drug: AT-1501

The purpose of this study is to compare outcomes of subjects undergoing multilevel lumbar fusion (MLF) surgery with and without the iFuse 3-D implant...

Active, not recruiting
Sacroiliac Joint Disruption
Scoliosis Lumbar Region
Device: iFuse 3-D in Bedrock Configuration
Procedure: Multilevel Lumbar Fusion surgery

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).The primary objective is to evaluate...

Enrolling
Idiopathic Pulmonary Fibrosis (IPF)
Drug: Placebo
Drug: INS018_055

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical...

Enrolling
Carcinoma, Squamous Cell
Cutaneous Squamous Cell Carcinoma
Drug: BCA101
Drug: Pembrolizumab

The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in t...

Enrolling
Heart Valve Diseases
Mitral Valve Insufficiency
Other: Guideline Directed Heart Failure Medication
Device: Carillon Mitral Contour System

Trial sponsors

University of Southern California logo

University of Southern California (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems